Software Treatment for Actively Reducing Severity of ADHD in Adults (STARS ADHD Adult)

Akili Interactive Labs

Status: Completed

Conditions: Attention Deficit Hyperactivity Disorder

Treatments: Other: Digital Treatment

Study type: Interventional

Funder types: Industry

Identifiers

NCT05183919

Akili-057

Details and patient eligibility

About

The purpose of this study is to evaluate the effects of the videogame-like digital therapy on attentional functioning and symptoms in Adults diagnosed with ADHD.

Full description

This study is a multi-center, unblinded/non-controlled adaptive design study to evaluate objective attention functioning and ADHD symptoms and impairments in adults with a diagnosis of ADHD (combined or inattentive subtype), stably on or off ADHD medication, after 6 weeks of AKL-T01 treatment.

A maximum of 325 total participants from 12-30 sites will be enrolled.

During the Screening/baseline, participants will undergo screening to evaluate eligibility for the study. Eligible participants will continue onto baseline procedures in the same visit.

Treatment phase (Day 2-42) will involve using the digital therapy at home for each participant. Compliance with treatment/use requirements will be monitored remotely during this phase.

An In-Clinic assessment will be completed on Day 42 to assess key outcomes.

Enrollment: 223 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Adults 18 years and older
2. Diagnosis of ADHD combined or inattentive type, according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as confirmed by Mini International Neuropsychiatric Interview (MINI) for Attention - Deficit / Hyperactivity Disorders Studies (Adult) 7.0.2
3. Stably on or off ADHD medications for ≥4 weeks prior to study enrollment and throughout the primary 6-week study
4. Stably on or off psychoactive medications for ≥4 weeks prior to study enrollment and throughout the 6-week study
5. Baseline visit score on the ADHD-RS-IV of ≥ 24
6. Baseline visit score on the TOVA-ACS score ≤ -1.8
7. Estimated IQ score ≥80 as assessed by the Kaufmann Brief Intelligence Test, Second Edition (KBIT-II)
8. Access to and self-report of ability to connect wireless devices to a functional wireless network
9. Ability to follow written and verbal instructions (English) as assessed by the PI and/or study coordinator
10. Able to comply with all testing and study requirements
11. Completion of informed consent form

Exclusion criteria

1. Current controlled or uncontrolled, comorbid psychiatric diagnosis with significant symptoms that in the opinion of the Investigator may confound study data/assessments.
2. Suicidality assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS)
3. Motor condition (e.g., physical deformity of the hands/arms) that prevents game playing as reported by the participant or observed by the Investigator.
4. History of moderate or severe substance use disorder within the last 12 months prior to informed consent
5. History of seizures (excluding febrile seizures), significant tics, or a current diagnosis of Tourette's Disorder.
6. Known sensitivity to playing video games, such as photo-sensitive epilepsy, light-headedness, dizziness, nausea, or motion sickness.
7. Color blindness as detected by Ishihara Color Blindness Test
8. Positive urine drug screen
9. Current or recent (3 months prior to screening) history of heavy smoking defined as the equivalent of greater than or equal to a pack of cigarettes a day
10. Any other medical condition that in the opinion of the Investigator may confound study data/assessments.
11. Participation in a clinical trial within 3 months prior to screening.
12. Previous exposure to Akili products within the 6 months prior to study enrollment
13. Plans to initiate new concomitant medications during the primary study, except for common over the counter (OTC) (e.g., ibuprofen, acetaminophen) and prescription medications (e.g., antibiotics) for minor transient ailments.
14. Planned initiation of, or significant changes in frequency, of non-pharmacological behavioral therapy during the primary study
15. Planned initiation of, or significant changes in frequency of, non-pharmacological trainings with the aim to improve cognition by means of game or app-based cognitive trainings or neurofeedback, during the primary study

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

223 participants in 1 patient group

AKL-T01

Experimental group

Description:

Digital treatment

Treatment:

Other: Digital Treatment